Evidence map›Paper›PMID 37418196›Full record

ArticleJournal of medicinal chemistry2023

Design, Synthesis, and Biological Evaluation of Novel Spiro Imidazobenzodiazepines to Identify Improved Inhaled Bronchodilators.

Daniel A Webb, Michelle J Meyer, Kayode M Medubi, Anika S Tylek, Gene T Yocum, M S Rashid Roni, Nicolas M Zahn, Sarah A Swartwout, Ahmad K Masoud, Charles W Emala and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Daniel A WebbDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Michelle J MeyerDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Kayode M MedubiDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Anika S TylekDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Gene T YocumDepartment of Anesthesiology, Columbia University, New York, New York 10032, United States.
M S Rashid RoniDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.ORCID 0000-0002-3105-0540
Nicolas M ZahnDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Sarah A SwartwoutDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Ahmad K MasoudDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.
Charles W EmalaDepartment of Anesthesiology, Columbia University, New York, New York 10032, United States.
Douglas C StaffordPantherics Incorporated, La Jolla, California 92037, United States.
Leggy A ArnoldDepartment of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, Wisconsin 53211, United States.ORCID 0000-0003-1411-1572
University of Wisconsin–Milwaukee · USColumbia University · US

Funding

Anesthetics' Effects on Physiological Responses Modulated by Peripheral GABAA ReceptorsR35GM140880 · NIGMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI EMALA, CHARLES W · 2021 to 2025
$2.0M
Development of new drugs for asthma by targeting GABA(A) receptors in the lungR01HL118561 · NHLBI · UNIVERSITY OF WISCONSIN MILWAUKEE · PI COOK, JAMES M · 2014 to 2017
$2.0M
GABAA Receptor-Mediated Modulation of Lung InflammationK08HL140102 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI YOCUM, GENE THOMAS · 2018 to 2022
$831k
Development of microencapsulated PI301 targeting lung GABAergic signalingR43HL162474 · NHLBI · PANTHERICS INCORPORATED · PI STAFFORD, DOUGLAS C. · 2022 to 2022
$256k
A novel asthma drug candidate targeting the GABAergic system in lung inflammationR41HL147658 · NHLBI · PANTHERICS INCORPORATED · PI ARNOLD, ALEXANDER · 2019 to 2019
$225k
NHLBI NIH HHS K08 HL140102NHLBI NIH HHS R01 HL118561NHLBI NIH HHS R41 HL147658NHLBI NIH HHS R43 HL162474NIGMS NIH HHS R35 GM140880
6 · The paper itself

Abstract

Novel gamma-aminobutyric acid receptor (GABA

Indexed as

Bronchodilator AgentsReceptors, GABA-AAnimalsgamma-Aminobutyric AcidGuinea PigsHumansLigandsMiceMolecular Docking SimulationBronchodilator Agentsgamma-Aminobutyric AcidLigandsReceptors, GABA-A

Identifiers

PMID37418196
PMCPMC10833105
OpenAlexW4383481327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.